| 1.16 -0.06 (-4.92%) | 04-24 11:33 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.09 | 1-year : | 2.67 |
| Resists | First : | 1.79 | Second : | 2.28 |
| Pivot price | 1.4 |
|||
| Supports | First : | 1 | Second : | 0.83 |
| MAs | MA(5) : | 1.26 |
MA(20) : | 1.48 |
| MA(100) : | 1.78 |
MA(250) : | 1.8 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 29.3 |
D(3) : | 31.9 |
| RSI | RSI(14): 33.8 |
|||
| 52-week | High : | 3.26 | Low : | 0.97 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TRAW ] has closed above bottom band by 16.3%. Bollinger Bands are 33.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.33 - 1.34 | 1.34 - 1.34 |
| Low: | 1.19 - 1.19 | 1.19 - 1.2 |
| Close: | 1.21 - 1.22 | 1.22 - 1.23 |
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Wed, 22 Apr 2026
Traws Pharma Q4 2025 Earnings Call Transcript - MarketBeat
Mon, 20 Apr 2026
Traws Pharma (TRAW) Stock Breakdown Level (Smart Money Flows) 2026-04-20 - Viral Momentum Stocks - UBND thành phố Hải Phòng
Mon, 20 Apr 2026
Traws Pharma (TRAW) Stock Breakdown Level (Smart Money Flows) 2026-04-20 - Alpha Picks - Cổng thông tin điện tử tỉnh Lào Cai
Mon, 20 Apr 2026
Traws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Zacks Investment Research
Wed, 15 Apr 2026
Backed by up to $60M, Traws pushes monthly flu drug toward trial - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 10 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 15.6 (%) |
| Held by Institutions | 33.6 (%) |
| Shares Short | 412 (K) |
| Shares Short P.Month | 520 (K) |
| EPS | 0.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.63 |
| Profit Margin | 328.6 % |
| Operating Margin | -640.7 % |
| Return on Assets (ttm) | -62.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -100 % |
| Gross Profit (p.s.) | 0.27 |
| Sales Per Share | 0.27 |
| EBITDA (p.s.) | -1.76 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 1.42 |
| PEG Ratio | 0 |
| Price to Book value | 1.82 |
| Price to Sales | 4.26 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|